Annual CFI
$95.47 M
+$87.53 M+1102.43%
December 31, 2024
Summary
- As of March 13, 2025, KPTI annual cash flow from investing activities is $95.47 million, with the most recent change of +$87.53 million (+1102.43%) on December 31, 2024.
- During the last 3 years, KPTI annual CFI has fallen by -$46.37 million (-32.69%).
- KPTI annual CFI is now -32.69% below its all-time high of $141.84 million, reached on December 31, 2021.
Performance
KPTI Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFI
$14.80 M
+$7.32 M+97.98%
December 31, 2024
Summary
- As of March 13, 2025, KPTI quarterly cash flow from investing activities is $14.80 million, with the most recent change of +$7.32 million (+97.98%) on December 31, 2024.
- Over the past year, KPTI quarterly CFI has stayed the same.
- KPTI quarterly CFI is now -71.13% below its all-time high of $51.26 million, reached on June 30, 2024.
Performance
KPTI Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFI
$95.47 M
-$12.05 M-11.20%
December 31, 2024
Summary
- As of March 13, 2025, KPTI TTM cash flow from investing activities is $95.47 million, with the most recent change of -$12.05 million (-11.20%) on December 31, 2024.
- Over the past year, KPTI TTM CFI has stayed the same.
- KPTI TTM CFI is now -32.99% below its all-time high of $142.47 million, reached on June 30, 2021.
Performance
KPTI TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Investing Formula
CFI = Cash Inflows from Investments − Cash Outflows for Investments
KPTI Cash From Investing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +1102.4% | 0.0% | 0.0% |
| 3 y3 years | -32.7% | 0.0% | 0.0% |
| 5 y5 years | +21.7% | 0.0% | 0.0% |
KPTI Cash From Investing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -32.7% | +191.6% | -71.1% | +122.7% | -32.7% | +177.9% |
| 5 y | 5-year | -32.7% | +191.6% | -71.1% | +122.7% | -33.0% | +177.9% |
| alltime | all time | -32.7% | +188.7% | -71.1% | +108.7% | -33.0% | +140.3% |
Karyopharm Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $95.47 M(+1102.4%) | $14.80 M(+98.0%) | $95.47 M(-11.2%) |
| Sep 2024 | - | $7.47 M(-85.4%) | $107.52 M(+16.4%) |
| Jun 2024 | - | $51.26 M(+133.6%) | $92.36 M(+48.3%) |
| Mar 2024 | - | $21.94 M(-18.3%) | $62.27 M(+684.2%) |
| Dec 2023 | $7.94 M(-107.6%) | $26.84 M(-449.3%) | $7.94 M(-109.4%) |
| Sep 2023 | - | -$7.68 M(-136.3%) | -$84.20 M(+29.9%) |
| Jun 2023 | - | $21.17 M(-165.4%) | -$64.84 M(-47.1%) |
| Mar 2023 | - | -$32.39 M(-50.4%) | -$122.61 M(+17.6%) |
| Dec 2022 | -$104.26 M(-173.5%) | -$65.30 M(-659.4%) | -$104.26 M(+1173.3%) |
| Sep 2022 | - | $11.67 M(-131.9%) | -$8.19 M(-623.2%) |
| Jun 2022 | - | -$36.60 M(+160.7%) | $1.56 M(-98.2%) |
| Mar 2022 | - | -$14.04 M(-145.6%) | $84.62 M(-40.3%) |
| Dec 2021 | $141.84 M(-364.2%) | $30.77 M(+43.6%) | $141.84 M(-0.4%) |
| Sep 2021 | - | $21.43 M(-53.9%) | $142.47 M(-0.0%) |
| Jun 2021 | - | $46.46 M(+7.6%) | $142.47 M(+296.0%) |
| Mar 2021 | - | $43.19 M(+37.5%) | $35.98 M(-167.0%) |
| Dec 2020 | -$53.69 M(-168.4%) | $31.40 M(+46.5%) | -$53.69 M(-54.7%) |
| Sep 2020 | - | $21.43 M(-135.7%) | -$118.60 M(+18.8%) |
| Jun 2020 | - | -$60.03 M(+29.2%) | -$99.86 M(>+9900.0%) |
| Mar 2020 | - | -$46.48 M(+38.7%) | -$20.00 K(-100.0%) |
| Dec 2019 | $78.45 M(-172.9%) | -$33.52 M(-183.4%) | $78.45 M(+785.5%) |
| Sep 2019 | - | $40.17 M(+0.9%) | $8.86 M(-182.4%) |
| Jun 2019 | - | $39.80 M(+24.4%) | -$10.75 M(-86.2%) |
| Mar 2019 | - | $31.99 M(-131.0%) | -$78.16 M(-27.4%) |
| Dec 2018 | -$107.66 M | -$103.11 M(-601.4%) | -$107.66 M(+1344.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | $20.57 M(-174.5%) | -$7.46 M(+0.4%) |
| Jun 2018 | - | -$27.60 M(-1211.3%) | -$7.43 M(-139.0%) |
| Mar 2018 | - | $2.48 M(-185.6%) | $19.04 M(+11.3%) |
| Dec 2017 | $17.11 M(-30.4%) | -$2.90 M(-114.1%) | $17.11 M(-35.7%) |
| Sep 2017 | - | $20.59 M(-1916.0%) | $26.61 M(+2453.8%) |
| Jun 2017 | - | -$1.13 M(-306.6%) | $1.04 M(-94.3%) |
| Mar 2017 | - | $549.00 K(-91.7%) | $18.39 M(-25.2%) |
| Dec 2016 | $24.59 M(-127.1%) | $6.60 M(-232.7%) | $24.59 M(-52.6%) |
| Sep 2016 | - | -$4.97 M(-130.7%) | $51.84 M(-48.9%) |
| Jun 2016 | - | $16.22 M(+140.2%) | $101.37 M(+17.9%) |
| Mar 2016 | - | $6.75 M(-80.1%) | $86.01 M(-194.7%) |
| Dec 2015 | -$90.82 M(+35.5%) | $33.84 M(-24.0%) | -$90.82 M(-51.8%) |
| Sep 2015 | - | $44.56 M(+5093.0%) | -$188.56 M(-19.9%) |
| Jun 2015 | - | $858.00 K(-100.5%) | -$235.40 M(-0.5%) |
| Mar 2015 | - | -$170.08 M(+166.2%) | -$236.59 M(+253.0%) |
| Dec 2014 | -$67.03 M(>+9900.0%) | -$63.90 M(+2695.1%) | -$67.03 M(+2016.5%) |
| Sep 2014 | - | -$2.29 M(+605.6%) | -$3.17 M(+249.6%) |
| Jun 2014 | - | -$324.00 K(-38.3%) | -$906.00 K(+55.7%) |
| Mar 2014 | - | -$525.00 K(+1540.6%) | -$582.00 K(+921.1%) |
| Dec 2013 | -$57.00 K(-52.9%) | -$32.00 K(+28.0%) | -$57.00 K(+128.0%) |
| Sep 2013 | - | -$25.00 K(<-9900.0%) | -$25.00 K(<-9900.0%) |
| Jun 2013 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2013 | - | $0.00 | $0.00 |
| Dec 2012 | -$121.00 K(-67.8%) | - | - |
| Dec 2011 | -$376.00 K | - | - |
FAQ
- What is Karyopharm Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Karyopharm Therapeutics?
- What is Karyopharm Therapeutics annual CFI year-on-year change?
- What is Karyopharm Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Karyopharm Therapeutics?
- What is Karyopharm Therapeutics quarterly CFI year-on-year change?
- What is Karyopharm Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for Karyopharm Therapeutics?
- What is Karyopharm Therapeutics TTM CFI year-on-year change?
What is Karyopharm Therapeutics annual cash flow from investing activities?
The current annual CFI of KPTI is $95.47 M
What is the all time high annual CFI for Karyopharm Therapeutics?
Karyopharm Therapeutics all-time high annual cash flow from investing activities is $141.84 M
What is Karyopharm Therapeutics annual CFI year-on-year change?
Over the past year, KPTI annual cash flow from investing activities has changed by +$87.53 M (+1102.43%)
What is Karyopharm Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of KPTI is $14.80 M
What is the all time high quarterly CFI for Karyopharm Therapeutics?
Karyopharm Therapeutics all-time high quarterly cash flow from investing activities is $51.26 M
What is Karyopharm Therapeutics quarterly CFI year-on-year change?
Over the past year, KPTI quarterly cash flow from investing activities has changed by $0.00 (0.00%)
What is Karyopharm Therapeutics TTM cash flow from investing activities?
The current TTM CFI of KPTI is $95.47 M
What is the all time high TTM CFI for Karyopharm Therapeutics?
Karyopharm Therapeutics all-time high TTM cash flow from investing activities is $142.47 M
What is Karyopharm Therapeutics TTM CFI year-on-year change?
Over the past year, KPTI TTM cash flow from investing activities has changed by $0.00 (0.00%)